Business Description
Karyopharm Therapeutics Inc
NAICS : 325412
SIC : 5999
ISIN : US48576U1060
Description
Financial Strength
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.84 | |||||
Equity-to-Asset | -0.83 | |||||
Debt-to-Equity | -1.04 | |||||
Debt-to-EBITDA | -1.45 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -10.76 | |||||
Beneish M-Score | -2.12 | |||||
WACC vs ROIC |
Growth Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -5.2 | |||||
3-Year EBITDA Growth Rate | 23.7 | |||||
3-Year EPS without NRI Growth Rate | 22.8 | |||||
3-Year FCF Growth Rate | 28.5 | |||||
Future 3-5Y Total Revenue Growth Rate | 15.09 |
Momentum Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 31.41 | |||||
9-Day RSI | 33.66 | |||||
14-Day RSI | 37.04 | |||||
6-1 Month Momentum % | 58.91 | |||||
12-1 Month Momentum % | -55.16 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 3.04 | |||||
Quick Ratio | 2.99 | |||||
Cash Ratio | 2.27 | |||||
Days Inventory | 217.81 | |||||
Days Sales Outstanding | 84.95 | |||||
Days Payable | 271.01 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -15.8 | |||||
Shareholder Yield % | 1.77 |
Profitability Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 96.08 | |||||
Operating Margin % | -94.26 | |||||
Net Margin % | -104.18 | |||||
FCF Margin % | -83.82 | |||||
ROA % | -54.66 | |||||
ROIC % | -876.28 | |||||
ROC (Joel Greenblatt) % | -2218.61 | |||||
ROCE % | -59.76 |
GF Value Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 0.78 | |||||
EV-to-EBIT | -1.15 | |||||
EV-to-EBITDA | -1.16 | |||||
EV-to-Revenue | 1 | |||||
EV-to-Forward-Revenue | 0.97 | |||||
EV-to-FCF | -1.2 | |||||
Price-to-Median-PS-Value | 0.03 | |||||
Earnings Yield (Greenblatt) % | -86.96 | |||||
FCF Yield % | -104.26 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Karyopharm Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 129.847 | ||
EPS (TTM) (€) | -1.173 | ||
Beta | -0.22 | ||
Volatility % | 87.36 | ||
14-Day RSI | 37.04 | ||
14-Day ATR (€) | 0.053063 | ||
20-Day SMA (€) | 0.9771 | ||
12-1 Month Momentum % | -55.16 | ||
52-Week Range (€) | 0.5866 - 2.219 | ||
Shares Outstanding (Mil) | 117.71 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Karyopharm Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Karyopharm Therapeutics Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Karyopharm Therapeutics Inc Frequently Asked Questions
What is Karyopharm Therapeutics Inc(STU:25K)'s stock price today?
When is next earnings date of Karyopharm Therapeutics Inc(STU:25K)?
Does Karyopharm Therapeutics Inc(STU:25K) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |